GlobeNewswire by notified

Wood Mackenzie Appoints Elena Belletti as Head of Carbon Research

Share

Joins from United Nations to lead growing carbon team

LONDON/HOUSTON/SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Wood Mackenzie, a Verisk business (Nasdaq:VRSK), has appointed Elena Belletti as Head of Carbon Research within the company’s Energy Transition Practice.

Based in Madrid, Elena joins from the United Nations (UN) Headquarters, where she had worked since 2015, most recently as an economist in the office for financing sustainable development. At the UN, Elena was the focal point on taxation and climate, advising senior government officials from low-income countries on the development of policies that generate revenues while protecting the environment. She also focused on carbon pricing and on the role of taxation in attaining environmentally-related sustainable development goals (SDGs). Prior to the UN, she was an economist for Palantir Economic Solutions and an advisor at Eni.

Head of Carbon is a newly expanded role at Wood Mackenzie, a trusted source of commercial intelligence for the world's natural resources sector. Elena will lead a team of five, responding to clients’ demands for tools and intelligence to help them through the energy transition. This includes the assessment and mitigation of their carbon emissions and an understanding of the fast-changing landscape around carbon mechanisms.

Jonny Sultoon, Head of Markets & Transitions, Energy Transition at Wood Mackenzie said: “Carbon and wider greenhouse gas emissions are a strategic focus for a growing number of clients in all industries. Elena’s appointment is particularly timely post-COP26, as governments have renewed or announced pledges to reduce both carbon and methane emissions to mitigate climate change, and industry and government will have to work collaboratively to align with these national commitments. Elena brings a cross-cutting understanding of the issues and governmental dynamics as well as stakeholder management experience. She is ideally suited to lead our carbon team.”

Elena Belletti added: “It is an exciting time to join Wood Mackenzie’s growing Energy Transition Practice. There is increasing demand from clients for data and support on all aspects of carbon, from emissions, price markets and mechanisms and voluntary markets to nature-based solutions, mechanical carbon removal and more. I look forward to working with such a talented team as we help clients achieve a fair energy transition.”

ENDS

For further information, please contact Wood Mackenzie’s media relations team:

The Big Partnership
+44 7711 281915
woodmac@bigpartnership.co.uk

Note to editors:
Read Elena Belletti’s thoughts on Carbon markets’ COP26 breakthrough in the latest edition of The Edge – weekly insight from Wood Mackenzie's Chairman and Chief Analyst Simon Flowers on the natural resources industry's biggest stories. 

About Wood Mackenzie
Wood Mackenzie, a Verisk Analytics business, is a trusted source of commercial intelligence for the world's natural resources sector. We empower clients to make better strategic decisions, providing objective analysis and advice on assets, companies and markets. For more information, visit: www.woodmac.com or follow us on Twitter @WoodMackenzie
WOOD MACKENZIE is a trademark of Wood Mackenzie Limited and is the subject of trademark registrations and/or applications in the European Community, the USA and other countries around the world.

About Verisk
Verisk (Nasdaq:VRSK) provides predictive analytics and decision support solutions to customers in the insurance, energy and specialized markets, and financial services industries. More than 70 percent of the FORTUNE 100 relies on the company’s advanced technologies to manage risks, make better decisions and improve operating efficiency. The company’s analytic solutions address insurance underwriting and claims, fraud, regulatory compliance, natural resources, catastrophes, economic forecasting, geopolitical risks, as well as environmental, social and governance (ESG) matters. Celebrating its 50th anniversary, the company continues to make the world better, safer and stronger, and fosters an inclusive and diverse culture where all team members feel they belong. With more than 100 offices in nearly 35 countries, Verisk consistently earns certification by Great Place to Work. For more: Verisk.comLinkedInTwitterFacebook and YouTube.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Verisk Welcomes Olumide Soroye to Its Board of Directors18.8.2022 22:15:00 CEST | Press release

JERSEY CITY, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK) today announced that Olumide Soroye has been appointed independent director of the company’s Board of Directors effective immediately. Soroye brings three decades of leadership experience across multiple industries. “Olumide’s experience in software, data analytics, AI, and growth-minded leadership make him an exceptional addition to Verisk’s board,” Verisk CEO Lee Shavel said. “We look forward to working closely with Olumide to ensure that we continue to drive value and positive impact for all Verisk stakeholders including shareholders, clients, employees and partners.” Soroye, 50, is president and chief executive officer of Fortive Corporation’s Intelligent Operating Solutions segment. Before Fortive, he held leadership roles at CoreLogic, where he was managing director of property intelligence & risk management, and QuinStreet, where he was senior vice president of the company’s technology and home services b

Galapagos receives transparency notification from FMR LLC18.8.2022 22:01:00 CEST | Press release

Mechelen, Belgium;18 August 2022, 22.01CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 15 August 2022 from FMR LLC, who notified that it holds 3,740,842 of Galapagos’ voting rights, consisting of 3,740,842 ordinary shares. FMR LLC controls investment funds FIAM Holdings LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,303,128 voting rights, and no longer holds any equivalent financial instruments, and Strategic Advisers LLC decreased its position to 10,082 voting rights. FMR LLC's holding of 3,740,842 Galapagos' voting rights represents 5.69% of Galapagos' currently outstanding 65,728,511 shares. FMR LLC thus remains above the 5% threshold of Galapagos’ voting rights considering the

Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines18.8.2022 20:24:11 CEST | Press release

U.S. FDA approved facility operated by Grand River Aseptic Manufacturing will assist in filling of already manufactured bulk vaccine to expedite deliveries of monkeypox vaccines to the U.S.Agreement will significantly expand Bavarian Nordic’s manufacturing capacity for the benefit of the U.S. and globallyExpedited tech transfer has already started, allowing for manufacturing of first doses in 2022 COPENHAGEN, Denmark, August 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a U.S. based contract manufacturer, for fill and finish of JYNNEOS smallpox/monkeypox vaccine. As announced on July 15, 2022, Bavarian Nordic received an additional order for 2.5 million doses the vaccine from the U.S. Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR), which will be filled at GRAM using bulk vaccine already ma

Bavarian Nordic udvider produktionskapaciteten via aftale med amerikansk kontraktproducent om fyldning af koppe-/abekoppevacciner18.8.2022 20:24:11 CEST | pressemeddelelse

Den FDA-godkendte kontraktproducent, Grand River Aseptic Manufacturing, vil bistå med fyldning af allerede produceret råvaccine med henblik på at fremskynde leverancer af abekoppevacciner til USAAftalen vil øge Bavarian Nordics produktionskapacitet markant til gavn for både USA og lamde globaltEn accelereret procesoverførsel er allerede startet, hvilket muliggør produktion af de første doser i 2022 KØBENHAVN, Danmark, 18. august 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en aftale med den amerikanske kontraktproducent Grand River Aseptic Manufacturing (GRAM) om fyldning af JYNNEOS koppe-/abekoppevaccine. Som meddelt den 15. juli 2022, modtog Bavarian Nordic en yderligere ordre på 2,5 mio. doser af vaccinen fra U.S. Biomedical Advanced Research and Development Authority (BARDA), en del af Administration for Strategic Preparedness and Response (ASPR), som vil blive påfyldt på GRAMs facilitet ved brug af den råvaccine, der allerede er fremstillet og fa

PCI Biotech: Company update18.8.2022 18:05:06 CEST | Press release

Oslo (Norway), 18 August 2022 – PCI Biotech (OSE: PCIB), a cancer-focused biopharma company developing innovative therapeutics that address significant unmet medical needs, today announced that the previously reported efforts to finance a planned Ph II trial in head and neck cancer have not under the current market conditions resulted in a feasible way forward. As PCI Biotech will not conduct a company-sponsored Ph II trial with the fimaVacc technology a reduction of the clinical team will be enacted during the second half of 2022. Further details about the development plans for the non-clinical assets will be given at the upcoming Q2 reporting, scheduled 31st August 2022. The cash position per Q2 2022 is around NOK 76 million and the financial runway is estimated to be towards the end of 2023. Contact information: Ronny Skuggedal, Interim CEO rs@pcibiotech.no Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutical company focusing on development and commercialisatio